Across TCGA pan-cancer cohorts, OR2L13 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated OR2L13 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR2L13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR2L13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
HNSC, UCEC, and STAD are the cancer types where OR2L13 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.